Published in Gene Therapy Weekly, June 14th, 2001
The class of drugs being studied is respirable antisense oligonucleotides (RASONs), pioneered by EpiGenesis. Multifactorial diseases include asthma, chronic obstructive pulmonary diseases, and many cancers.
The data were presented at the "Antisense 2001, Advances in EpiGenetic Medicine" international conference, sponsored by the scientific publication, Nature Biotechnology.
"We have found occurrences of near total...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.